Prometheus Biosciences, Inc.(RXDX) Stock Research - Grey Stern Research

Prometheus Biosciences, Inc. (RXDX) Stock Analysis

$199.92 (0.09%)

RXDX Financial Performance


Use the table below to view Prometheus Biosciences, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q1 - 2023

Metric Value Ranking among Peers
Price $199.92 -
52 Week Low $23.27 -
52 Week High $199.96 -
Market Cap $9.6 Billion 2/18
Gross Margin 100% 1/18
Profit Margin -100% 15/18
EBITDA margin -4408% 18/18
Q1 - 2023 Revenue $1.1 Million 11/18
Q1 - 2023 Earnings -$33.0 Million 7/18
Q1 - 2023 Free Cash Flow -$40.1 Million 9/18
Trailing 4 Quarters Revenue $4.0 Million 11/18
Trailing 4 Quarters Earnings -$140.3 Million 11/18
Quarterly Earnings Growth -3% 9/18
Annual Earnings Growth -15% 11/18
Quarterly Revenue Growth -72% 15/18
Annual Revenue Growth 32% 8/18
Cash On Hand $113.3 Million 11/18
Short Term Debt $3.5 Million 5/18
Long Term Debt $26.0 Million 11/18

Prometheus Biosciences, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Prometheus Biosciences, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 3/18
PS 2392.62 2/18
PB 13.70 3/18
PC 84.33 3/18
Liabilities to Equity 0.09 15/18
ROA -0.19 9/18
ROE -0.20 5/18
Current Ratio 12.47 4/18
Quick Ratio 11.74 4/18
Long Term Debt to Equity 0.04 11/18
Debt to Equity 0.04 11/18
Burn Rate 3.24 7/18
Cash to Cap 0.01 14/18
CCR 1.21 2/18
EV to EBITDA -194.54 16/18
EV to Revenue 2371.62 2/18

Company Details

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.

CEO: Mr. Mark C. McKenna

Website: https://www.prometheusbiosciences.com

Address: 9410 Carroll Park Drive San Diego, CA

Exchange: NASDAQ Global Select

Industry: Biotechnology

Prometheus Biosciences, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Prometheus Biosciences, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Viking Therapeutics, Inc. VKTX $3.2 Billion
Reata Pharmaceuticals, Inc. RETA $6.6 Billion
Intercept Pharmaceuticals, Inc. ICPT $794.7 Million
Madrigal Pharmaceuticals, Inc. MDGL $7.5 Billion
Blueprint Medicines Corporation BPMC $5.7 Billion
Apellis Pharmaceuticals, Inc. APLS $3.0 Billion
Krystal Biotech, Inc. KRYS $5.4 Billion
IVERIC bio, Inc. ISEE $5.5 Billion
Karuna Therapeutics, Inc. KRTX $12.6 Billion
Stoke Therapeutics, Inc. STOK $440.7 Million
Immunovant, Inc. IMVT $3.3 Billion
89bio, Inc. ETNB $1.2 Billion
Pliant Therapeutics, Inc. PLRX $94.9 Million
Terns Pharmaceuticals, Inc. TERN $284.5 Million
Day One Biopharmaceuticals, Inc. DAWN $834.2 Million
Roivant Sciences Ltd. ROIV $7.7 Billion
Arcellx, Inc. ACLX $3.8 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement

Latest News

RXDX Income Statements
Quarter Year Revenue Earnings
Q1 2023 $ 1.1 Million -$33.0 Million
Q3 2023 $ 1.1 Million -$40.9 Million
Q4 2022 $ 653,000 -$36.3 Million
Q2 2023 $ 653,000 -$38.8 Million
Q3 2022 $ 968,000 -$37.3 Million
Q2 2022 $ 1.3 Million -$33.6 Million
Q1 2022 $ 3.9 Million -$32.1 Million
Q4 2021 $ 295,000 -$29.9 Million

View All

RXDX Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2023 $113.3 Million $758.4 Million $29.5 Million $697.6 Million
Q1 2023 $113.3 Million $758.4 Million $29.5 Million $697.6 Million
Q2 2023 $292.4 Million $740.8 Million $29.5 Million $676.0 Million
Q4 2022 $292.4 Million $740.8 Million $29.5 Million $676.0 Million
Q3 2022 $78.4 Million $298.6 Million $29.2 Million $232.5 Million
Q2 2022 $96.0 Million $237.6 Million $14.8 Million $191.8 Million
Q1 2022 $227.0 Million $253.6 Million $891,000 $206.7 Million
Q4 2021 $257.3 Million $267.8 Million $0 $235.2 Million

View All

RXDX Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2023 -$40.1 Million -$530,000 -$179.1 Million
Q1 2023 -$40.1 Million -$530,000 -$179.1 Million
Q2 2023 -$13.6 Million -$1.9 Million $214.0 Million
Q4 2022 -$41.5 Million -$369,000 $214.0 Million
Q3 2022 -$52.2 Million $1.1 Million -$17.5 Million
Q2 2022 -$58.2 Million $25,000 -$131.1 Million
Q1 2022 -$30.3 Million -$955,000 -$30.2 Million
Q4 2021 $0 $0 $0

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions